Skip to content

A trial drug for Polycystic Ovarian disease

A pilot study of Karbhakandhi ennai for the treatment of PCOS (Sinaipaineerkatti)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/06/004709
Enrollment
10
Registered
2014-06-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Irregular Menstrual cycles

Interventions

Intervention1: Karbagandhi Ennai Internal for Sinaipaineerkatti: Karbagandhi Ennai is a herbomineral drug given 3-5 drops OD dose for three months. Control Intervention1: Nil: Nil

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Irregular menstrual cycle: Eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer. •Patients having polycystic ovary on ultrasound should either have 12 or more follicles measuring 2-9 mm in diameter, or have an increased ovarian volume of 10 CC or greater •Patient willing for Ultrasound abdomen and blood investigations. •Patient willing to sign the informed consent

Exclusion criteria

Exclusion criteria: •Presence of any pelvic pathology such as chronic pelvic infection, Pelvic endometriosis, Adenomyosis, Uterine fibroid, Endometrial Polyp. •Presence of secondary endocrine disorder such as hyperprolactinaemia, thyroid dysfunction. •Patient using oral contraceptives or use of fertility drugs within 6 months •Presence of any associated severe systemic illness.

Design outcomes

Primary

MeasureTime frame
â?¢Normal appearing of ovary confirmed by TV USG or Confirming of normal follicles being formed and ruptured through folliculogram. â?¢Establishing regularization of menstrual cycle.Timepoint: 6-9 months

Secondary

MeasureTime frame
â?¢Enhancing weight reduction with a BMI 30. â?¢Reducing elevated hormone levels like testosterone and DHEAS.Timepoint: Follow-up of the patients for three menstrual cycles;â?¢Enhancing weight reduction with a BMI 30. â?¢Reducing elevated hormone levels like testosterone and DHEAS.Timepoint: Follow-up of the patients for three menstrual cycles

Countries

India

Contacts

Public ContactMMeenakshi Sundaram

National Institute Of Siddha

sk.keerthana@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026